Prion finding offers insight into spontaneous protein diseases July 29
Prion
finding offers insight into spontaneous protein diseases; (July 29, 2004)
University of California - San Francisco
UCSF scientists are reporting what they say is compelling evidence that the
infectious agent known as prion is composed solely of protein. Their findings
promise to create new tools for early diagnosis of prions causing bovine
spongiform encephalopathy, or "mad cow" disease, in cattle and
Creutzfeldt-Jakob disease in people, they say. The researchers believe that
their work may also help advance investigations of more common neurodegenerative
diseases, such as Alzheimer's disease, Parkinson's disease and amyotrophic
lateral sclerosis.
The
finding is reported in the July 30 issue of Science.
In the study, the researchers created a large fragment of the normal prion
protein -- a harmless protein found in all mammals examined. They then folded
this fragment into the abnormal shape that they suspected would give it the
infectious properties of the prion. Next, they injected the folded protein
fragment into the brains of mice genetically engineered to over express the same
fragment, but with the shape of the normal prion protein. After a year, the mice
developed prion disease and brain tissue from the inoculated mice was injected
into wild-type mice that subsequently developed prion disease in about half a
year.
"Our
study demonstrates that misfolding a particular segment of the normal prion
protein is sufficient to transform the protein into infectious prions,"
says the lead author of the study, Giuseppe Legname, PhD, UCSF assistant adjunct
professor of neurology in the laboratory of the senior author Stanley B.
Prusiner, MD, UCSF professor of neurology and director of the UCSF Institute for
Neurodegenerative Diseases.
"A
great deal of evidence indicates that prions are composed only of protein, but
this is the first time that this has been directly shown in mammals. The
challenge in the last few years has been to figure out exactly how to
demonstrate that prions are made entirely of protein."
SPONTANEOUS
PRION DISEASES
The discovery that a small change in the condition of a cell can cause the
development of a prion offers an explanation, says Prusiner, for the sporadic
form of Creutzfeldt Jakob disease (CJD), which is responsible for 85 percent of
cases of prion disease in humans (occurring in 1 or 2 people per million) and is
believed to develop spontaneously. It also supports his belief, he says, that
sporadic forms of prion disease are caused by prion strains that are different
from the one causing bovine spongiform encephalopathy (BSE) in cattle in
Britain. He says he thinks that sporadic BSE will be found in one to five cattle
per million and predicts such numbers will be found with increased testing for
BSE.
"The
finding represents a renaissance in prion biology," says Prusiner.
"For the first time, we can create prions in the test tube, which will
change the way scientists do experiments in the field. We now have a tool for
exploring the mechanism by which a protein can spontaneously fold into a shape
that causes disease."
More
broadly, he says, the advance may lead to similar changes in the way studies are
conducted for other neurodegenerative diseases that involve protein
misprocessing, including Alzheimer's disease, Parkinson's disease and
amyotrophic lateral sclerosis. While it is not clear that a protein changes
shape in all these diseases, each involves a particular protein that undergoes
some form of misprocessing, in terms of a shape change, metabolism or
degradation, or proteolysis. It is not clear which of these forms of
misprocessing occurs in each disease, says Prusiner. However, as in prion
diseases, the misprocessing involves a profound conformational change that most
often occurs spontaneously.
"The
insights that scientists have made into the spontaneous misprocessing of prion
proteins have already aided progress in studies of other neurodegenerative
diseases," says Prusiner. "But we hope that our new findings with
synthetic prions will help scientists investigating other neurodegenerative
diseases to move one step further in understanding how misprocessing is
spontaneously initiated, and how it progresses."
The
production of synthetic prions is the latest milestone in the 30-year effort by
UCSF scientists to move in on the biochemical composition of the elusive agent,
which causes a variety of similar rare, fatal, brain-destroying diseases,
including sporadic CJD and variant CJD, in humans, BSE, or "mad cow"
disease, in cattle, scrapie in sheep, and like illnesses in deer, elk and mink.
PRION'S FATAL DANCE
The
researchers have long maintained that a prion does not contain nucleic acid, the
genetic material of life (DNA or RNA). Viruses, which have a nucleic acid core,
replicate by high jacking the machinery of a cell and using it to synthesize
more nucleic acid. In contrast, prions are an aberrant form of a normal protein
(thus composed of amino acids) that form when a particular segment of normal
prion protein in the brain's nerve cells, or neurons, loses its corkscrew-shape
structure (known as an alpha helix) and flattens into so-called beta sheets.
They suspect that individual normal prion proteins (PrPC) occasionally misform
in all people and relevant animals, but are routinely "cleared," or
removed, from brain cells. However, in rare cases, they suspect, the abnormal
protein, or prion (PrPSc), is not cleared.
Once
conversion occurs, they hypothesize, the prion moves on to other normal prion
proteins, pinning and flattening their spirals, and thus, initiating a process
that occurs repeatedly, akin to a deadly Virginia reel in the brain. The
accumulation and aggregation of the flattened beta sheets leads to structural
damage of the nerve cells, causing cell degradation that generally leads to
death in less than a year. Prions can arise spontaneously, result from an
inherited mutation in prion protein gene or develop through infection from an
exogenous source.
When
the protein-only theory was postulated by Prusiner, in 1982, it was met with
skepticism. In subsequent years, the UCSF scientists and numerous other groups
have reported substantial evidence to support the hypothesis, reflected in the
fact that Prusiner was awarded the Lasker Prize, in 1994, and the Nobel Prize in
Physiology or Medicine, in 1997, for the discovery "of prions -- a new
biological principal of infection," which he named prion (PREE-on), for
proteinacious infectious protein. Still, despite the wealth of scientific
studies producing evidence to support the theory, a direct, straightforward test
the prion theory has eluded researchers until now.
The
goal has been to create a bonafide prion in the lab, which would be proven to be
such by its ability to infect animals and cause a fatal illness. The challenge,
says Prusiner, has been the inability to determine the details of the prion's
three-dimensional structure at the atomic level. "If we knew this," he
says, "we could have designed a physical assay that would tell us we are
now making PrPSc in the test tube."
The
new study represents the latest tactic by Prusiner and his colleagues to get
around this block: working from the belief that beta-sheet-rich structures
harbor prion infectivity, but without knowing which segments are responsible,
the team set out to create a synthetic agent made up of a subset of
beta-sheet-rich structures that assemble into amyloid fibers, which they
hypothesized might contain some prion infectivity.
THE
RESEARCH
Following the strategy used to establish that a virus or bacterium is the cause
of a particular infectious disease, UCSF scientists reported 20 years ago that
prions purified from brains of rodents that were clumped into amyloid fibrils
triggered disease when injected into the brains of healthy animals, and produced
mad cow-like brain pathology.
Because
prions are unprecedented, UCSF scientists wanted to go one step further and
produce synthetic prions. The scientists chose to produce a fragment of the
normal PrP in E. coli since bacteria are known not to carry prions. The fragment
was chosen because it corresponds in length to the truncated PrP that assembles
infectious amyloid fibrils when purified from infected brains.
The scientists purified the PrP fragment from E. coli and then altered its
conformation so that it might become an infectious prion. They did this by
taking the segment of the protein that they know has the capacity to form
amyloid, and placing it in a shaking device to promote amyloid formation. They
tracked the process with thioflavin T, a dye that fluoresces in the presence of
amyloid.
After 40 hours, amyloid was detected. To accelerate the reaction time, the team
then took some of these amyloid fibrils, and used them as a "seed" for
the production of nascent amyloid fibrils in a second shaking tube. This time
amyloid fibrils were detected after 10 hours. These were called
"seeded" amyloid fibrils.
To
determine if the PrP fragment was infectious, Prusiner and his colleagues used
transgenic mice making the same PrP fragment. Importantly, the mice express
truncated PrP at 16 times the level that PrP is normally made in wild-type mice.
The over expression of the PrP fragment in these mice shortens the incubation
times, which already approach the lifespan of mice. Prusiner and his colleagues
also thought that if the truncated PrP expressed in the transgenic mice
corresponded precisely to the PrP fragment produced in bacteria, this would
provide the most sensitive system for detecting newly formed prions.
Notably,
amyloid is a structure that, depending on the protein it contains, has been
implicated in a number of brain diseases including Alzheimer's and Parkinson's
diseases. After about 300 days, with none of the transgenic mice sick, the
researchers were ready to declare the study a failure. But then, at 380 days,
one of the mice showed symptoms of a prion-like disease. Eventually, all of the
inoculated mice showed neurologic disease, the last one 660 days after
injection.
Prusiner
and his colleagues then inoculated more transgenic as well as wild-type mice
with brain extract prepared from one of the sick mice. The prions in the brain
extract caused disease in about 150 days in the wild-type mice and in about 90
days in transgenic mice expressing full-length PrP.
In
each case, on the primary passage, the scientists detected four hallmarks of
prion disease -- (1) clinical signs of neurologic dysfunction (ataxia, or loss
of motor coordination, and rigidity), (2) neuropathologic changes in the brain (vacuolation,
deposits of PrPSc and astrocytic gliosis), (3) resistance of PrPSc to breakdown
by protease and (4) most importantly serial transmission of prion infectivity to
wild-type and other transgenic mice.
While
the results strongly indicate that the subset of beta-sheet-rich structure
represented by amyloid harbors prion infectivity, the scientists report that
they have preliminary evidence that other beta-sheet-rich structures may also
harbor prion infectivity. And they are interested in producing prion
preparations that have much higher levels of prion infectivity than the two
reported.
"Our findings gives us the opportunity to start exploring prions on a new
level," says Legname.
Co-authors
of the study were Ilia V. Baskakov, PhD, who, at the time the study was started
was a postdoctoral fellow in the UCSF Institute for Neurodegenerative Diseases (IND),
and is now at University of Maryland in Baltimore; Hoang-Oanh B. Nguyen, a staff
research assistant in the UCSF/IND; Detlev Riesner, professor of biochemistry at
the Institut fur Physikalische Biologie, Heinrich-Heine Universitat, Dussedldorf,
Germany; Fred E. Cohen, PhD, UCSF adjunct professor of pharmacology, and Stephen
J. DeArmond, PhD, UCSF professor of pathology and neuropathology.